# Design and rationale of the EFFORTII project: a multicentric randomised-controlled trial on the impact of continued nutritional therapy at hospital discharge

**Authors:** Carla Wunderle, Pascal Tribolet, Nina Kaegi-Braun, Valerie Haller, Robert Escher, Drahomir Aujesky, Gisele Trennepohl Da Costa Heinen, Michael Brändle, Thomas Bregenzer, Christoph Henzen, Thomas Zehnder, Susanne Schait, Christina Gassmann, Maja Dorfschmid, María D Ballesteros-Pomar, Cristina Cuerda, Rosa Burgos, Daniel De Luis, Gabriel Olveira, Leocardio Rodriguez-Mañas, Zeno Stanga, Beat Mueller, Philipp Schuetz

PMC · DOI: 10.1136/bmjopen-2025-115456 · BMJ Open · 2026-03-18

## TL;DR

This study tests if continued nutritional support after hospital discharge improves outcomes for malnourished patients.

## Contribution

The EFFORTII trial is the largest randomized trial to assess long-term nutritional therapy's impact on mortality and recovery after hospital discharge.

## Key findings

- The trial is designed to evaluate if individualized nutritional therapy reduces mortality and complications.
- It uses a combination of telemedicine and in-person consultations for nutritional support.
- The study is event-driven, aiming to reach 247 mortality events over approximately 5 years.

## Abstract

Malnutrition is a highly prevalent chronic condition that contributes to higher morbidity and mortality in patients with multiple comorbidities. While positive effects of nutritional therapy in the in-hospital setting have recently been demonstrated, the benefits of long-term nutritional therapy after hospital discharge remain uncertain. Herein, we outline the design and rationale of the EFFORTII trial, the largest nutritional trial to date to assess the effects of continued nutritional support after hospital discharge in medical patients, with particular attention to key design decisions regarding nutritional strategy, patient selection criteria and study endpoints.

The Effect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery (EFFORTII) is an investigator-initiated, non-commercial randomised controlled trial designed to evaluate whether ongoing, individualised nutritional therapy after hospital discharge—targeted to meet specific energy and protein requirements—offers a cost-effective approach to lowering mortality, minimising complications and maintaining functional status compared with standard care. Eligible participants are adult, chronically ill medical inpatients at risk of malnutrition. Patients in the intervention group receive individualised nutritional therapy delivered by an experienced dietitian through a combination of telemedicine and in-person consultations. The intervention aims to meet personalised nutritional targets, supported by a trained dietitian. Control group patients receive nutritional counselling at discharge, but no structured nutritional management during follow-up. We designed the trial as an event-driven trial with a target of 247 mortality events (primary endpoint), which will be assessed over approximately 5 years until event-driven endpoint is met. The minimum total sample size is at least 802 participants, based on the assumed treatment HR of 0.70. The main trial is enrolling patients across multiple sites in Switzerland. During the trial, additional sites in Spain joined the study, and their data will be analysed using a patient-level pooled approach.

This study involves human participants and was first granted ethical approval by the Ethics Committee Northwest- and Central Switzerland and then by all participating local ethics committees. Written informed consent will be obtained from all participants. Findings will be disseminated in peer-reviewed journals and academic conferences.

NCT04926597.

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** inflammation (MESH:D007249), chronic kidney disease (MESH:D051436), COVID-19 (MESH:D000086382), nutritional deficits (MESH:D009748), anorexia (MESH:D000855), chronic heart failure (MESH:D006333), acute liver failure (MESH:D017114), weight loss (MESH:D015431), cancer (MESH:D009369), pulmonary embolism (MESH:D011655), Chronic Disease (MESH:D002908), dementia (MESH:D003704), myocardial infarction (MESH:D009203), acute renal failure (MESH:D058186), chronic renal failure (MESH:D007676), cardiac arrest (MESH:D006323), COPD (MESH:D029424), gastrointestinal disease (MESH:D005767), diabetes (MESH:D003920), Frailty (MESH:D000073496), functional impairment (MESH:D003072), muscle wasting (MESH:D009133), food insecurity (MESH:D005517), intestinal perforation (MESH:D007416), energy and protein deficiencies (MESH:D011502), Damage (MESH:D020263), Acute pancreatitis (MESH:D010195), Disease-related malnutrition (MESH:D044342), death (MESH:D003643), bacterial infection (MESH:D001424), haemorrhage (MESH:D006470), decline (MESH:D060825), infection (MESH:D007239), intracranial bleeding (MESH:D013345), stroke (MESH:D020521)
- **Chemicals:** steroid hormones (MESH:D013256), maltodextrin (MESH:C008315)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13007153/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13007153/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC13007153/full.md

---
Source: https://tomesphere.com/paper/PMC13007153